Dynamic Nanomaterials for Drug Delivery and Diagnostics
Event details
| Date | 15.05.2013 |
| Hour | 15:30 › 16:30 |
| Speaker |
Prof. Patrick Stayton, University of Washington, Seattle, WA (USA) Bio: Dr. Stayton is the director of the Institute for Molecular Engineering and Sciences and the Center for Intracellular Delivery of Biologics. He received his B.S. in biology (summa cum laude) from Illinois State University, his Ph.D. in biochemistry from the University of Illinois, and he was a postdoctoral research associate at the Beckman Institute for Advanced Science and Technology, also at the University of Illinois. Dr. Stayton’s eclectic research group works at the interface of fundamental molecular science and applied molecular bioengineering. His laboratory has pioneered new drug delivery systems for biologic drugs and vaccines and new nanotechnologies for diagnostic and regenerative technologies. Dr. Stayton has a strong interest in translating the group’s research, has been awarded several patents, and is a co-founder of two start-up companies: PhaseRx Inc., based on his group’s drug delivery work, and Nexgenia, based on their diagnostic work. Dr. Stayton has been elected as a fellow of the American Institute for Medical and Biological Engineering and has received the Clemson Award from the Society for Biomaterials and the CRS-Cygnus Recognition Award from the Controlled Release Society. He served as co-chair of the Gordon Conference on Drug Carriers in Medicine and Biology in 2010. He has also been awarded the 2009 Faculty Research Innovation Award in the UW College of Engineering, a Distinguished Teacher and Mentor Award from the Department of Bioengineering, and an honorary award from the College of Engineering’s Minority Science and Engineering Program. |
| Location | |
| Category | Conferences - Seminars |
Our group develops stimuli-responsive nanomaterials that utilize dynamic structural and architectural transitions to enable new drug delivery and diagnostic functionalities. For drug delivery applications we are focused on opening the intracellular target universe to biologic drugs. Biologic drugs such as DNA, RNA and proteins have significant therapeutic potential, but effectively formulating and delivering them remains a widely recognized challenge. Barriers include drug stability, tissue penetration and transport, but cytoplasmic entry is a widespread barrier for those that function against intracellular disease targets. We have been developing synthetic polymeric carriers that mimic the highly efficient intracellular delivery systems found in pathogenic viruses and organisms. Another important aspect of these polymeric carriers is the development of controlled polymerization techniques to streamline bioconjugation of targeting agents and therapeutics, as well as to generate controlled carrier architectures. The carriers might open up new families of peptide, antibody or nucleic acid drug candidates that attack previously inaccessible intracellular targets. For diagnostic applications we are addressing the technology gap for making clinical assays faster and more sensitive, as well as the need for simple yet efficient sample handling techniques that concentrate dilute biomarkers for point-of-care (POC) tests. We have developed a new stimuli-responsive magnetic nanoparticle reagent system for achieving both of these goals. These new bioanalytical systems are being applied to clinical lab assays, lab card disposable devices and for non-instrumented lateral flow diagnostic platforms.
Links
Practical information
- Informed public
- Free
- This event is internal
Organizer
- Prof. Matthias Lutolf
Contact
- Institute of Bioengineering (Dietrich Reinhard)